Biotech Values

[zigzagman]

Yeah...It wasn't as bad of a bloodbath as I expected...

It did drop below my buy in level of .17 briefly after it opened the regular session, but I did NOT sell...It sure had a nice bounce back to nearly .24 by 11am...

The news wasn't really that bad...There was nothing wrong with the DRUG itself, and is still very approveable...

The RTF letter was caused by a minor technicality about the manufacturing process that's fairly easily rectified...

I listened to the CC, and thought they did a decent job of damage control...Maybe they've learned something from this, and won't make the same mistakes on the NDA for ANX-514 which is the real money maker here...ANX-530 is a drop in 514's bucket as far as potential revenue is concerned...

So we get a six month or so delay...It's not the end of the world for this one...IF they screw up this NDA again, or the one for 514, I'll have some SERIOUS doubts about the management of this company...